GeneDx, one of the world’s foremost genetic testing laboratories and a subsidiary of Bio-Reference Laboratories, Inc. announced today its intention to launch a suite of comprehensive genetic tests for inherited cancers including BRCA1 and BRCA2 genes. GeneDx, which was the first commercial laboratory to utilize next generation sequencing technologies to answer meaningful clinical questions in cardiology, neurology, ophthalmology, among other clinical areas, will now bring its expertise and reputation for service to inherited cancers and will offer a 27-gene panel for breast and ovarian cancers. GeneDx will also provide next generation sequencing based multi-gene panels for gastrointestinal and colorectal cancers, pancreatic cancer, endometrial cancer and renal cell carcinoma. GeneDx has distinguished itself and gained the trust of the genetics community for its clinical and scientific expertise and experience. Founded in 2000 by geneticists and still managed today by geneticists, GeneDx started offering Whole Exome Sequencing in 2012 to help end the diagnostic odyssey for families who for years have been looking for a molecular diagnosis. Currently, GeneDx offers testing for more than 350 genetic disorders, and has over 30 board-certified geneticists and genetic counselors on staff available to physicians to address their concerns and questions about genetic testing.
